Source: Pharmacy Times articles
An expert discusses CAR T therapy’s potential in treating relapsed multiple myeloma, highlighting long-term remissions and access challenges.
Recent Content
- Regulation of stress tolerance by CREB1 sustains multiple myeloma cell survival
- (no title)
- (no title)
- (no title)
- (no title)
- (no title)
- (no title)
- (no title)
- Daily pill to stop pancreatic cancer spread granted FDA orphan drug status
- CD4+ T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy